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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S253safety and upper gastrointestinal (UGI) tolerability, deﬁned as  1
moderate to severe event of nausea, abdominal pain, or dyspepsia.
Results: 362 patients were randomized and received treatment; 81
discontinued prematurely (27 celecoxib, 37 naproxen, 17 placebo), and
286 were included in the efﬁcacy valuable population (121 celecoxib,
107 naproxen, 58 placebo). Patient ages ranged from 42 to 90 years,
with means of 65.9, 64.1, and 63.9 years for celecoxib, naproxen, and
placebo, respectively. Most patients were female (67%-68%). Mean
duration of OA was 4.5, 4.8, and 4.6 years for celecoxib, naproxen, and
placebo, respectively, with a range of 0.1 to 38.0 years. Mean changes in
Patient's Assessment of Arthritis Pain (VAS) from baseline to Week 6/
early terminationwere -37 mm, -38 mm, and -34 mm for the celecoxib,
naproxen, and placebo treatment groups, respectively. For the primary
end point, celecoxib was observed to be as effective as naproxen in
reducing OA pain (difference in least squares means -0.4, standard error
2.5, 95% conﬁdence interval -5.2 to 4.5). No statistically signiﬁcant
differences were observed between celecoxib and naproxen in the
Patient's and Physician's Global Assessment of Arthritis, theWOMACOA
Index scores, UGI tolerability, the Pain Satisfaction Scale, and the PHQ-9.
UGI events, speciﬁcally, moderate or severe nausea, abdominal pain,
and/or dyspepsia, were experienced by 16 patients (5/145 [3%] in the
celecoxib group, 9/141 [6%] in the naproxen group, and 2/76 [3%] in the
placebo group). No statistically signiﬁcant differences in UGI tolerability
were observed among the treatment groups.
Conclusions: Celecoxib 200 mg qd was as effective as naproxen 500mg
bid in the treatment of the signs and symptoms of OA of the knee in
Asian American patients in a trial designed to evaluate this population
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Purpose: The purpose of these 2 identically designed studies (Study 1,
Study 2) was to compare the efﬁcacy and safety of celecoxib 200 mg
once daily (qd) with placebo in patients with osteoarthritis (OA) of the
knee who previously were nonresponsive to or did not tolerate treat-
ments with both naproxen and ibuprofen (prescription strength).
Methods: Both trials were 6-week randomized, double-blind, parallel-
group, placebo-controlled, multicenter concurrent trials. Patients aged
 40 years with active symptomatic OA of the knee in a ﬂare state and
with an American College of Rheumatology functional capacity classi-
ﬁcation I to III at baseline visit were eligible for randomization to either
celecoxib 200 mg qd or placebo in a 1:1 ratio. The previous treatment
durations of naproxen (at least 750 mg/d) and ibuprofen (at least 1200
mg/d) had to be a minimum of 2 weeks if failure was due to lack of
efﬁcacy and for any duration if failure was due to lack of tolerability. The
primary efﬁcacy variable in both trials was the change in the Patient's
Assessment of Arthritis Pain using a 100-mm visual analog scale (VAS)
at 6 weeks compared with baseline. The primary analysis compared
each trial separately for an intent-to-treat population. Safety assess-
ments included adverse events (AEs).
Results: In Study 1, 380 patients (mean age z 60 years) were
randomized. The majority of patients in the celecoxib and placebo
groups were female (62.1% and 58.9%, respectively) and white (71.6%
and 73.7%, respectively). At Week 6, the least squares mean (LSM)
decrease from baseline in the Patient's Assessment of Arthritis Pain
(VAS) in the celecoxib group was signiﬁcantly better than placebo (27.3
vs 14.9; P< 0.001). The proportion of patients reporting AEs was similar
in the celecoxib and placebo groups (all causality: 25.0% and 25.1%,
respectively; treatment-related: 6.4% and 5.3%, respectively). In Study 2,
388 patients (mean agez 58 years) were randomized. The majority of
patients in the celecoxib and placebo groups were female (71.3% and
64.2%, respectively) and just over one half were white (51.8% and 56.5%,
respectively). At Week 6, there was no signiﬁcant difference (P ¼ 0.183)
between the celecoxib (28.0 mm) and placebo (24.6 mm) groups in the
LSM change from baseline for the Patient's Assessment of Arthritis Pain
(VAS). The proportion of patients reporting AEs in the celecoxib and
placebo groups, respectively, was 22.2% and 26.2% for all-causality AEs;
6.2% and 11.5% for treatment-related AEs.
Conclusions: These 2 identically designed, concurrent, controlled trials
of celecoxib 200 mg qd vs placebo in patients with OA who previouslydid not respond to, or did not tolerate, treatment with naproxen and
ibuprofen, showed mixed results. For the primary end point of the
patient's assessment of pain, celecoxib was better than placebo in one
study but not in the other study. Celecoxib was well tolerated in both
trials. These discordant results highlight the challenges inherent in
treating OA of the knee in patients who failed previous nonsteroidal
anti-inﬂammatory drugs.484
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Purpose: Biomechanical factors are known to be important in the
pathogenesis of OA however their assessment in clinical practice has
been limited due to need for sophisticated gait laboratory assess-
ments. Clinical decision making can be enhanced by access and
interpretation of useful information during the clinical encounter.
Theoretically osteoarthritis management (both the selection of inter-
vention and its intensity) can differ according to presenting clinical
features and clinician guidance. The knowledge relating to the deter-
mination of what biomechanical features are helpful in guiding ther-
apeutic decision making in osteoarthritis (OA) is limited. The purpose
of this investigation was to determine if knee kinematic measure-
ments were associated with other clinical factors associated with knee
OA such as quality of life, functional performance and depression and
therefore could be used in guiding clinical decision making in OA
management.
Methods: We selected a consecutive series of participants with knee
OA from the Osteoarthritis Chronic Care Program (OACCP). The OACCP
is a chronic disease rehabilitation program which aims to increase
functional capacity and manage co-morbidities, emphasising physical
activity and healthy weight management. In the OACCP, each partici-
pant is assessed by a multidisciplinary team. The team provides an
individualised intervention program in addition to education about OA
and any identiﬁed co-morbidities. This approach enables realistic goal
setting and optimal self-management. Data (including KOOS, DASS
(Depression anxiety stress scale), EQ5D quality of life measure, and
functional performance) is collected from assessments at 0, 12, 26 and
52 weeks into the OACCP and recorded on an electronic platform
provided. Key health outcomes for participants include the level of
pain experienced in the affected joint(s) and the ability to function in
activities of daily life. Three-dimensional (3D) knee kinematics data:
ﬂexion/extension, abduction/adduction and tibial internal / external
rotation (respectively in the frontal, sagittal, and transverse planes)
were recorded from each participant while walking on a treadmill at
a self-selected comfortable speed using a portable 3D knee kinematic
analyser, KneeKGTM. The 3D kinematics were recorded during two
gait trials of 25 sec. Non-parametric correlation and multiple regres-
sion analysis were performed to study an association between knee
kinematic and health outcome measures in knee OA OACCP
participants.
Results: 60 knees from 52 persons with knee OA were assessed. 52%
were female, their mean age was 68.6 years, mean BMI of 30.7kg/m2.
The total range of ﬂexion/extension motion (mean amplitude
49.29.8) in 90% of cohort was inferior compared to a typical walking
pattern. All 60 (100%) had limited ﬂexion excursion during loading
(Table 1). The amplitude of the adduction/abduction (mean 9.23.5)
was distributed among the patients with 15 (25%) being below, 16
(27%) within and 29 (48%) above the normal walking pattern (Figure
1). Limited ﬂexion/extension was associated with presence of
depression and anxiety (p<.01), reduced functional performance on
the TUG (p<.02) and impaired quality of life (activities p<.01). Higher
varus angle at initial contact was associated with impaired quality of
life (activities p<.01).
Conclusions: A portable kinematic assessment identiﬁed a high
frequency of mechanical abnormalities in a cohort of persons with knee
OA. The validity of these kinematic measures is supported by associa-
tions with impaired quality of life, reduced functional performance and
depression. This information was useful in guiding tailored and indi-
vidualised clinical care.
